

Failed clinical trials cost a lot of money.

What if failure was avoidable?

My Intelligent Machines is a new way forward, helping life scientists harness the power of human and artificial intelligence to push the boundaries of drug development.

We are a software-as-a-service (SaaS) company, with an augmented-intelligence platform leveraging systems biology, distributed computing, and machine learning to unleash the power of reverse translational research. MIMs is changing the research paradigm for endotype characterization, indications prioritization, and target and biomarker discovery, in oncology, immune-related disorders, infectious diseases, and more.

Predict good responders to new therapies with **more than 2X higher performance** than other available methodologies

Generate results at **one tenth of the cost** of consulting services

Complete **a month's work in a single day**

Quantify future trial success to **attract investment**

Move **therapies to the clinic faster**

- ▶ Automate data management and processing
- ▶ Operate with industry-leading security and compliance
- ▶ Work code-free in a platform designed for life scientists
- ▶ Wholly own your IP
- ▶ Empower teams with greater autonomy
- ▶ Focus on high-value strategic activities

We've created a machine helping humans identify therapeutic solutions neither could find alone

- » **Better understand patient heterogeneity** to better understand why patients respond differently to treatments
- » **Identify better drug targets** knowing the clinical and molecular characteristics of high-value patient groups
- » **Identify good responders at pre-clinical stages** to better select patients for clinical trials and accelerate companion test development

A funded, big-pharma-validated multi-omic solution changing lives

Life scientists and clinicians can interact directly with their data where previously they had to rely on colleagues and consultants.

Bioinformaticians can focus where they add the most value: in the strategic analysis of data.

Breaking outdated research models and approaches

Sarah Jenna, Mickaël Camus, and Abdoulaye Baniré Diallo—visionaries in systems biology, bioinformatics, and artificial intelligence—created My Intelligent Machines in 2016. They saw an opportunity to spark ground-breaking creativity at the discovery, pre-clinical, and clinical stages of drug discovery, and haven't looked back since. Today, MIMs' transformational SaaS solutions are made possible by an inclusive team of remarkable and diverse humans – present and future leaders in their respective fields. This team, guided by humble and humanistic principles, has brought a machine to life.

12 PhDs

8 software engineers

4 AI specialists

9 data scientists


290+ scientific articles combined

20 countries of origin

15 languages spoken

How it all works

MIMs' platform integrates our MIMsight Knowledge Base—which combines billions of data points and other information extracted from scientific literature, public databases, and multi-omic and clinical patient data—and our proprietary GI² algorithm inferring genetic interactions within patient tumors and immune systems. These vivid human cartographies of individual patients deliver previously unimagined levels of precise insight used to classify patients into subgroups, identify their molecular and clinical characteristics, predict their response to new therapies, and identify powerful therapeutic targets and biomarkers.



▶ Patient Classification and Characterization

- Patient clusters
- Molecular and clinical profiles

▶ Target Discovery

- Targets
- Molecular and clinical profiles of good responders

▶ Indication Prioritization for Clinical Trials

- Input: drug target
- Output: % good responders per indication

▶ Biomarker Discovery

- Drug or disease biomarkers - multiomic signatures
- From liquid or solid biopsies

About MIMs

MIMs is a software-as-a-service (SaaS) company with an augmented-intelligence platform leveraging systems biology, distributed computing, and machine learning to unleash the power of reverse translational research. Delivering higher performance 30 times faster and at one tenth the cost of other approaches, MIMs is changing the research paradigm for endotype characterization, indications prioritization, and target and biomarker discovery, in oncology, immune-related disorders, infectious diseases, and more.

Schedule a demo to learn more.

info@mims.ai • mims.ai



/ My Intelligent Machines